ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2029

Aberrant H3K9me3 Modification in Promoter Region Up-regulates cAMP Response Element Modulator Alpha in Systemic Lupus Erythematosus

Huilin Zhang 1 and Qing Zhang2, 1Clinical Nursing Teaching and Research Section, Second Xiangya Hospital, Central South University, Changsha, Hunan, China (People's Republic), 2Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China (People's Republic)

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Systemic lupus erythematosus (SLE), T cells and Histone Modification

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: SLE – Etiology & Pathogenesis Poster II

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: In recent years, accumulating evidences have demonstrated that increased cAMP response element modulator α (CREMα) which can inhibit IL-2 and induce IL-17A in CD4+ T cells plays an essential role in the pathogenesis of systemic lupus erythematosus (SLE). However, the molecular mechanisms that result in CREMα over expression remain poorly understood. The aim of this study is to investigate the mechanisms that regulate CREMα expression in SLE.

Methods: CD4+ T cells were isolated from healthy controls and SLE patients. Histone H3 lysine 9 trimethylation (H3K9me3, a hallmark associated with transcription inhibition) enrichments at various gene promoters in CD4+ T cells from 5 healthy controls and 5 SLE patients were analyzed by chromatin immunoprecipitation (ChIP) microarray. Amounts of H3K9me3, H3K9 methyltransferases SUV39H1 and SUV39H2 within the CREMα promoter were subsequently assessed by ChIP and real-time PCR in CD4+ T cells from 15 healthy controls and 15 SLE patients. And CREMα mRNA levels were determined by real-time RT-PCR.

Results: From the ChIP microarray data, we identified sharply decreased H3K9me3 enrichment at the CREMα promoter of SLE CD4+ T cells compared to healthy controls. Then by ChIP and real-time PCR experiments, we confirmed this finding. In addition, H3K9me3 enrichment at the promoter was negatively correlated with CREMα mRNA level in SLE CD4+ T cells. Moreover, a markedly decrease was observed in SUV39H1 binding, but no significant change in SUV39H2 enrichment at the CREMα promoter region in SLE CD4+ T cells. We also proved SUV39H1 binding was positively correlated with H3K9me3 amount at the CREMα promoter, and negatively correlated with CREMα mRNA level in CD4+ T cells from SLE patients.

Conclusion: Our findings suggest for the first time that decreased SUV39H1 binding down-regulates H3K9me3 enrichment at the CREMα promoter, which induces CREMα overexpression in SLE CD4+ T cells, and results in the development of SLE at last.


Disclosure: H. Zhang, None; Q. Zhang, None.

To cite this abstract in AMA style:

Zhang H, Zhang Q. Aberrant H3K9me3 Modification in Promoter Region Up-regulates cAMP Response Element Modulator Alpha in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/aberrant-h3k9me3-modification-in-promoter-region-up-regulates-camp-response-element-modulator-alpha-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/aberrant-h3k9me3-modification-in-promoter-region-up-regulates-camp-response-element-modulator-alpha-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology